Tamoxifen for early breast cancer: An overview of the randomised trials Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Clinical Trials as Topic
  • Neoadjuvant Therapy
  • Neoplasm, Residual
  • Practice Guidelines as Topic

abstract

  • For women with tumours that have been reliably shown to be ER-negative, adjuvant tamoxifen remains a matter for research. However, some years of adjuvant tamoxifen treatment substantially improves the 10-year survival of women with ER-positive tumours and of women whose tumours are of unknown ER status, with the proportional reductions in breast cancer recurrence and in mortality appearing to be largely unaffected by other patient characteristics or treatments.

authors

publication date

  • May 16, 1998

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0140-6736(97)11423-4

PubMed ID

  • 9605801

Additional Document Info

start page

  • 1451

end page

  • 67

volume

  • 351

number

  • 9114